Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis

Rabenhorst, Anja; Christopeit, Bastian; Leja, Silke; Gerbaulet, Alexander; Kleiner, Svea; Förster, Anja; Raap, Ulrike; Wickenhauser, Claudia; Hartmann, Karin

doi:10.1016/j.jaci.2013.06.019

Cited by 53 publications

(36 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients have higher levels of IL-6 and RANKL leading to an increase in bone resorption and higher levels of serum sclerostin possibly contributing to a decrease in Wnt signaling and bone formation (175) . However, the mechanisms responsible for osteoporosis and increased fracture risk need further study so that targeted therapies can be evaluated.…”

Section: Introductionmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management

Mirza

Canalis

2015

European Journal of Endocrinology

267

164

View full text Add to dashboard Cite

Osteoporosis is a skeletal disorder characterized by decreased bone mineral density and compromised bone strength predisposing to an increased risk of fractures. Although idiopathic osteoporosis is the most common form of osteoporosis, secondary factors may contribute to the bone loss and increased fracture risk in patients presenting with fragility fractures or osteoporosis. Several medical conditions and medications significantly increase the risk for bone loss and skeletal fragility. This review focuses on some of the common causes of osteoporosis, addressing the underlying mechanisms, diagnostic approach and treatment of low bone mass in the presence of these conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management

Mirza

Canalis

2015

European Journal of Endocrinology

267

164

View full text Add to dashboard Cite

show abstract

“…Mast cell deficiency has been associated with low remodelling states, whereas their excess is associated with accelerated bone absorption . The production of bone cytokines by mastocytes in osteopenic and osteoporotic patients has been suggested to shift the balance of bone turnover towards increased bone resorption and decreased bone formation . Unfortunately, human studies addressing whether or not mast cell inhibition can be beneficial in osteoporosis are rare, and data evaluating bone mineral density or even fracture risk are limited .…”

Section: Discussionmentioning

confidence: 99%

Chronic urticaria and osteoporosis: a longitudinal, community‐based cohort study of 11 944 patients

et al. 2019

View full text Add to dashboard Cite

Background Chronic urticaria (CU) carries many risk factors for osteoporosis, but data on the relationships between CU and osteoporosis are lacking. Objectives To evaluate the association between CU and osteoporosis in a large community-based study. Methods A nationwide observational longitudinal cohort study was conducted. CU was defined as four pairs of urticaria diagnoses; each pair was recorded within a period of 6 weeks and was registered by physicians in a primary-care setting. Patients with CU and their age-and sex-matched controls were followed for the incidence of osteoporosis and other laboratory data between 2002 and 2017. Data regarding systemic steroid exposure and other relevant risk factors for osteoporosis were obtained. Analyses of risk for osteoporosis were performed in Cox regression models adjusted for age, sex, exposure to systemic corticosteroids, obesity, smoking and hyper-and hypothyroid disease. Results The study included 11 944 patients with CU and 59 829 controls. During the study's observation period, 1035 (8Á7%) patients with CU were diagnosed with osteoporosis, compared with 4046 (6Á8%) controls. The adjusted multivariate analysis demonstrated that CU was significantly associated with a higher risk for osteoporosis (hazard ratio 1Á23, 95% confidence interval 1Á10-1Á37, P < 0Á001). Conclusions CU may impose a risk for osteoporosis. Appropriate targeted screening should be considered.

show abstract

“…Up to 30 % of patients with mastocytosis experience osseous involvement in the form of osteopenia (with/without lytic lesions)/osteoporosis (with/without atraumatic fractures) as well as osteosclerosis with increased density or isolated lytic lesions . Bone‐related cytokines – RANKL (receptor activator of nuclear factor kappa‐B ligand), OPG (osteoprotegerin), and SOST (sclerostin) – are elevated in patients with ISM and can interfere with bone remodeling .…”

Section: Symptomsmentioning

confidence: 99%

Mastocytosis – pathogenesis, clinical manifestation and treatment

Wagner¹,

Staubach

2018

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary The term mastocytosis designates a group of rare disorders characterized by typical skin lesions, frequently associated episodes of anaphylaxis, and clinical symptoms related to the release of various mediators. Dermatologists/allergists are frequently the first to establish the diagnosis. The condition is based on clonal mast cell proliferation, usually in the skin or bone marrow and only rarely in the gastrointestinal tract or other tissues. In general, mastocytosis has a good prognosis in terms of life expectancy. Rare variants – including mast cell leukemia, aggressive mastocytosis, and the exceedingly rare mast cell sarcoma – require cytoreductive therapy. In cases associated with hematological neoplasms, the prognosis depends on the underlying hematologic disorder.

show abstract

Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis

Cited by 53 publications

References 8 publications

MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management

MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management

Chronic urticaria and osteoporosis: a longitudinal, community‐based cohort study of 11 944 patients

Mastocytosis – pathogenesis, clinical manifestation and treatment

Contact Info

Product

Resources

About